EP4025187
Lyfjagjafarmeðferð sem tengist inndælanlegum samsetningum af palíperídón með forðalosun
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
7.5.2021EP published:
3.1.2024EP application number:
21724651.1
EP translation filed:
11.3.2024Grant published:
15.4.2024EPO information:
European Patent Register
Max expiry date:
6.5.2041Expiry date:
6.5.2026Next due date:
31.5.2026
Title in English:
DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMULATIONSLanguage of the patent:
English
Timeline
Today
7.5.2021EP application
3.1.2024EP Publication
11.3.2024Translation submitted
15.4.2024Registration published
6.5.2026Expires
Owner
Name:
Janssen Pharmaceutica NVAddress:
Turnhoutseweg 30, 2340 Beerse, BE
Inventor
Name:
GOPAL, SrihariAddress:
Titusville, NJ 08560, US
Name:
VENKATASUBRAMANIAN, RajaAddress:
Titusville, NJ 08560, US
Name:
T'JOLLYN, HuybrechtAddress:
2340 Beerse, BE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202063119382 PDate:
30.11.2020Country:
US
Classification
Categories:
A61K 9/00, A61K 9/10, A61K 31/519, A61P 25/18, A61P 25/24
Annual fees
Number
Paid
Expires
Payer
Number: 4
Paid: 5.4.2024
Expires: 6.5.2025
Payer: Árnason Faktor ehf.
Number: 5
Paid: 29.4.2025
Expires: 6.5.2026
Payer: Árnason Faktor ehf.